Ole Halfdan Larsen

Dr. Ole Halfdan Larsen


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2020 in Cells
Verified
Journal Article
Open access
PDF file
MBMarianne Trier Bjerre
Marianne Trier Bjerre
MNMaibritt Nørgaard
Maibritt Nørgaard
OLOle Halfdan Larsen
Ole Halfdan Larsen
SJSarah Østrup Jensen
Sarah Østrup Jensen
SSSiri Strand
Siri Strand
KSKarina D Sørensen
Karina D Sørensen
Novel and minimally-invasive prostate cancer (PCa)-specific biomarkers are needed to improve diagnosis and risk stratification. Here, we investigated the biomarker potential in localized and de novo metastatic PCa (mPCa) of methylated circulating tumor DNA (ctDNA) in plasma. Using the Marmal-aid database and in-house datasets, we identified three top candidates specifically hypermethylated in PCa tissue: DOCK2, HAPLN3, and FBXO30 (specificity/sensitivity: 80%–100%/75–94%). These candidates were further analyzed in plasma samples from 36 healthy controls, 61 benign prostatic hyperplasia (BPH), 102 localized PCa, and 65 de novo mPCa patients using methylation-specific droplet digital PCR. Methylated ctDNA for DOCK2/HAPLN3/FBXO30 was generally not detected in healthy controls, BPH patients, nor in patients with localized PCa despite a positive signal in 98%–100% of matched radical prostatectomy tissue samples. However, ctDNA methylation of DOCK2, HAPLN3, and/or FBXO30 was detected in 61.5% (40/65) of de novo mPCa patients and markedly increased in high- compared to low-volume mPCa (89.3% (25/28) vs. 32.1% (10/31), p < 0.001). Moreover, detection of methylated ctDNA was associated with significantly shorter time to progression to metastatic castration resistant PCa, independent of tumor-volume. These results indicate that methylated ctDNA (DOCK2/HAPLN3/FBXO30) may be potentially useful for identification of hormone-naïve mPCa patients who could benefit from intensified treatment.

1 March 2019 in Thrombosis Research
Verified
Journal Article
Closed access
AKAlisa Kjaergaard
Alisa Kjaergaard
OLOle Halfdan Larsen
Ole Halfdan Larsen
AHAnne-Mette Hvas
Anne-Mette Hvas
PNPeter H. Nissen
Peter H. Nissen

30 December 2025 in Research Square
Verified
Preprint
Open access
PDF file
JBJohan Bundgaard
Johan Bundgaard
SRSøren Rand
Søren Rand
MBMette Bentsen
Mette Bentsen
OPOle Birger Vesterager Pedersen
Ole Birger Vesterager Pedersen
ESErik Sørensen
Erik Sørensen
JGJonas Ghouse
Jonas Ghouse
Fibrotic diseases show common pathophysiological features irrespective of their anatomical locations. By mapping the genomic landscape behind selected fibrotic diseases, we aim to investigate the genome-wide and locus-wide genetic overlap across fibrotic diseases. We conducted genome-wide meta-analyses using five genetic cohorts (Copenhagen Hospital Biobank (CHB), the Danish Blood Donor Study (DBDS), UK Biobank (UKB), FinnGen, the Million Veteran Program (MVP)) across 17 fibrotic traits comprising nine prototypical fibrotic diseases (e.g. carpal tunnel syndrome and idiopathic pulmonary fibrosis), four organ-diseases with known fibrotic components (e.g. heart failure and chronic kidney disease), and four imaging-derived fibrotic phenotypes. Global genetic correlations across fibrotic traits were estimated using linkage disequilibrium score regression (LDSC) and Locus-wide genetic overlaps were evaluated using colocalization analyses. Across 17 fibrotic traits with case sample sizes ranging from 4,559 for Peyronie’s disease to 126,358 for chronic kidney disease, we identified 645 genome-wide significant associations, of which 136 had not been reported previously for the respective trait. Using genetic correlation and hierarchical clustering, we found that fibrotic diseases clustered mainly into organ and non-organ specific clusters. The strongest correlations were between carpal tunnel syndrome and trigger finger ( r g = 0.60, P = 1.1 × 10 −63 ) and between chronic kidney disease and heart failure ( r g = 0.51, P = 9.5 × 10 −87 ). We identified 64 loci that colocalized across traits, of which 12 overlapped with three or more diseases. Many of the colocalizing genes belonged to gene families with established roles in fibrosis, including WNT signaling ( WNT7B , TCF7L2 , and WNT2 ), extracellular matrix ( COL11A1, MMP14 and P4HA2 ), fibroblast growth factors ( FGFR2, FGF21 ), and inflammation ( IRF5, STAT3 , and TNFAIP3 ). Our findings identified novel genetic variants and provide strong evidence for a shared genetic predisposition across fibrotic traits, converging on key biological pathways including extracellular matrix remodeling, immune regulation, and developmental signaling.